Overview

This project aims to establish the cancer genome atlas and the platform of recurrence risk prediction specific for East Asian breast cancer patients. The study was planned to collect blood sample, fresh tumor tissue, and paraffin embedded tumor tissue from 2000 patients. Aims to identify unique genetic alterations in Asian tumors, to identify the susceptible genes for breast carcinogenesis in East Asia, and to establish the new platform for accurate prediction of recurrence. The investigator will explore the association of patient outcomes with the genetic alterations from the cancer atlas of East Asian breast tumors.

Eligibility

Inclusion Criteria:

• 1. Aged more than 20-year-old at the time of informed consent.
• 2. An unconfirmed breast tumor, or have histologically confirmed invasive breast cancer.
• 3. Have radiological or objective evidence of breast tumor size ≥1 cm.
• 4. Be able to comply with study procedures to collect the clinical medical information, blood sample, fresh tumor tissue, and 12 sections of paraffin embedded tumor tissue.
• 5. Be able to sign an informed consent.

Exclusion Criteria:

• 1. Have histologically confirmed ductal carcinoma in situ (DCIS).
• 2. Stage I, II or III breast cancer patients who have received neoadjuvant treatments, including chemotherapy, hormonal therapy, or targeted therapy.
• 3. Stage IV or metastatic breast cancer patients who have received chemotherapy.